David Gandara: Multi-omics approach to plasma testing proves effective in colorectal cancer screening
Yuji Uehara, Medical Oncologist at National Cancer Center Hospital East, Komagome Hospital, shared a post on X/Twitter by David Gandara, Medical Oncologist and clinical-translational researcher in lung cancer at UC Davis Comprehensive Cancer Center, adding:
“The cfDNA and multitarget stool DNA tests in NEJM are buzzing topics! While sensitivity for precancerous lesions is low, tech brilliance will solve this challenge. Should this breakthrough hit lung cancers, how to intervene with premalignancy becomes crucial for patients.”
Quoting David Gandara’s post below:
“Hot off the press! “Multi-omics” approach (genomics, epigenomics, proteomics) to plasma testing proves effective in colorectal cancer screening. Hoping same will be seen in other cancer types.”
Sources: Yuji Uehara/X and David Gandara/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023